Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing innovative treatments to combat progressive retinal diseases, will be participating in the H.C. Wainwright BioConnect Conference on May 2, 2023.
Held in collaboration with NASDAQ at their world headquarters in New York City (151 West 42nd Street), this one-on-one meeting offers a unique opportunity to gain insight into Opthea’s cutting-edge research and its potential to revolutionize the treatment of retinal diseases.
About Opthea Limited
Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company on a mission to revolutionize the treatment of retinal diseases, such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Its lead product candidate, OPT-302, is currently undergoing Phase 3 clinical trials with the aim of providing broader inhibition of the VEGF family than current anti-VEGF-A monotherapies, in order to improve efficacy and drive superior visual outcomes.